The skeleton is a mineral reservoir that plays a key metabolic role in the maintenance of systemic phosphorus/calcium homeostasis as well as an endocrine organ. Coordination of mineral homeostasis relies on the coupled mechanisms of absorption by the intestine, bone remodeling and kidney excretion that are traditionally viewed from the perspective of the PTH/vitamin D axis. We are beginning to recognize the importance of a novel hormonal axis involving FGF23, which is produced by osteocytes in bone. FGF23 targets the kidney to inhibit renal phosphate reabsorption and serves as a counterregulatory hormone for 1,25(OH) 2 (6) . Since PTH effects might be mediated through a cAMP-dependent mechanism, these findings are consistent with earlier reports of increased FGF23 in patients with McCune Albright's syndrome caused by activating mutations in GNAS1. On the other hand, other investigations found that reduction in bone turnover by administration of OPG or alendronate to mice is accompanied by increased FGF23 levels (7) . In these studies, PTH administration decreased FGF23 in association with increased bone turnover. Interestingly, the activation in osteocytes of PTHR1 and elevations of FGF23 expression (6) are also associated with periosteal bone formation through activation of Wnt signaling and suppression of Sost (8) . A similar concomitant increase in FGF23 expression, activation of the Wnt-β-catenin pathway and decreased expression of Sost is also observed in Phex-deficient hypomineralized cortical bone (4). Finally, the complete deletion of PTH in Fgf23(-/-) mice, which already display low PTH levels, partially restores their bone phenotype (9) . These unexpected results, however, might be explained by the reduction in elevated 1,25(OH) 2 D levels after deletion of PTH in Fgf23(-/-) mice. Thus, the role of PTH in regulating FGF23 is uncertain, and may reflect both indirect effects on 1,25(OH) 2 D or other pathways as well as differences in bone remodeling derived from acute and chronic administration of PTH.
Circulating levels of biologically active fulllength FGF23 are also regulated by proteolytic processing by a furin-like convertase and the glycosyl transferase, GALNT3. Loss of GALNT3, which is seen in the disease familial tumoral calcinosis, results in only inactive C-terminal FGF23 in the circulation, and indicates that Oglycosylation may be important in preventing FGF23 degradation by furin (10). In fact, the O-glycosylation level of FGF23 can also be modulated by cAMP which inhibits GALNT3 (11).
The end-organ effects of FGF23 are restricted due to the limited expression of the transmembrane co-receptor αKlotho, which determines its specificity for the FGF receptor (FGFR). FGF23 induces phosphate wasting by down-regulating Napi2a cotransporters in the proximal tubule of the kidney, whereas αKlotho is predominately expressed in the renal distal tubules, suggesting the possibility of a paracrine cross-talk between the distal and proximal tubules. Klotho also exists as a circulating form. The presence of a soluble secreted Klotho that can impart an FGF23 effect on FGFR-expressing tissues is discordant with the apparent tissue-restricted function of FGF23. For example, bone that does not express Klotho has been proposed to be a target for FGF23. Whether physiological concentrations of soluble Klotho might permit FGF23 to affect bone is unknown. In vitro studies of cultured osteoblasts supplemented with FGF23 and αKlotho reveal a dose-dependent response of increased proliferation and lower mineralization (12). Besides, soluble Klotho permitted activation of the canonical Wnt pathway following FGF23 signaling in vitro (13) .
In the presence of normal renal function, three Na-dependent Pi co-transporters, Npt2a, Npt2b and Npt2c, are involved in the control of systemic phosphate balance. The creation of Npt2b knockout mice revealed the importance of Npt2b in the intestinal absorption of Pi (14). The loss of this transporter resulted in an unchanged phosphatemia with increased fecal Pi excretion combined with reduced urinary Pi, elevation of 1,25(OH) 2 D3 and lower FGF23 serum levels. These changes were not associated with any skeletal disorders. On the other hand, Npt2a and Npt2c are implicated in the regulation of phosphate reabsorption in the kidney. Different FGFR signaling pathways might be activated in response to FGF23 to result in internalization of Napi2a/Napi2c from the renal brush border membrane. Possibilities include the MAPK, AKT, PKC, PLC-γ and Src pathways (15). It has been shown that FGF23 injection in mice induces pERK1/2 activation in the distal tubule but not in the proximal tubule shortly after injection and that Napi2a downregulation occurs in the proximal tubule only 20 to 50 minutes after pERK1/2 activation (16). This suggests again the presence of a factor communicating between the distal and the proximal tubules to inhibit phosphate reabsorption following FGF23 signaling. On the other hand, the existing idea that FGFR1c is the primary target for FGF23 was challenged by studies showing that upon stimulation with FGF23, FGFR3, but not FGFR1, was activated in proximal tubular cells (15). Additional work is needed to clarify the tubular segments, molecular targets, and function of FGF23 in the kidney.
